Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CLDN6/CD3 bispecific antibody CTIM-76

An Fc-silenced humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CLDN6/CD3 bispecific antibody CTIM-76 targets and binds to both CLDN6 expressed on tumor cells and CD3 expressed on T cells. This activates and redirects cytotoxic T lymphocytes (CTLs) to CLDN6-expressing tumor cells, which leads to enhanced CTL-mediated killing of CLDN6-expressing tumor cells. CLDN6, a tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not or minimally expressed on normal, healthy adult cells.
Synonym:anti-CD3/CLDN6 bispecific antibody CTIM-76
anti-Claudin-6/CD3 bispecific antibody CTIM-76
anti-CLDN6/anti-CD3 bispecific antibody CTIM-76
anti-CLDN6/CD3 T-cell engaging bispecific antibody CTIM-76
Claudin-6-directed bispecific antibody CTIM-76
CLDN6 T-cell engager antibody CTIM-76
CLDN6 x CD3 bispecific antibody CTIM-76
CLDN6 x CD3 T-cell engaging bispecific antibody CTIM-76
CLDN6-directed TCE CTIM-76
Code name:CTIM 76
CTIM-76
CTIM76
Search NCI's Drug Dictionary